Tandem Diabetes (TNDM) Tops Q3 EPS by 6c, Beats on Revenue; Offers FY24 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Deutsche Bank cuts gold outlook as Fed repricing weighs on prices
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Tandem Diabetes Care (TNDM) PT Lowered to $59 at Leerink Partners
November 7, 2024 5:57 AM ESTLeerink Partners analyst Mike Kratky lowered the price target on Tandem Diabetes Care (NASDAQ: TNDM) to $59.00 (from $62.00) while maintaining a Outperform rating.
The analyst comments "Bottom Line: Despite posting another commanding topline beat (+9% vs. cons.), TNDM was bidding down high singledigits % post-market. We are... More
